Healius Limited (ASX:HLS)

Australia flag Australia · Delayed Price · Currency is AUD
0.980
-0.005 (-0.51%)
At close: Dec 5, 2025
-29.50%
Market Cap 711.61M
Revenue (ttm) 1.34B
Net Income (ttm) -151.20M
Shares Out 726.13M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE 50.13
Dividend 0.41 (42.14%)
Ex-Dividend Date May 9, 2025
Volume 695,436
Average Volume 2,408,863
Open 0.985
Previous Close 0.985
Day's Range 0.975 - 0.997
52-Week Range 0.662 - 1.635
Beta 0.37
RSI 58.92
Earnings Date Nov 19, 2025

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ... [Read more]

Sector Healthcare
Founded 1994
Employees 8,224
Stock Exchange Australian Securities Exchange
Ticker Symbol HLS
Full Company Profile

Financial Performance

In 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.

Financial Statements

News

There is no news available yet.